SCHEMBL4096827

SCHEMBL4096827

Fc1ccc(-c2nc(N3CCCC3)c3ccccc3n2)cc1F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACP1 P24666 2/20 0.70
HIF1A Q16665 1/20 0.64
TSHR P16473 4/20 0.64
USP2 O75604 2/20 0.64
KMT2A Q03164 2/20 0.64
MEN1 O00255 1/20 0.64
LMNA P02545 3/20 0.62
MAPT P10636 3/20 0.62
ABCG2 Q9UNQ0 3/20 0.59
MAPK1 P28482 2/20 0.58
NPSR1 Q6W5P4 2/20 0.58
HSD17B10 Q99714 2/20 0.58
ALDH1A1 P00352 1/20 0.58
ABCB1 P08183 1/20 0.55
SMAD3 P84022 1/20 0.55
TP53 P04637 2/20 0.55
L3MBTL1 Q9Y468 2/20 0.54
METAP1 P53582 1/20 0.54
RAB9A P51151 1/20 0.54
TDP1 Q9NUW8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084433 0.99 ACP1 (0.71) ACP1HIF1ATSHRUSP2KMT2A
SCHEMBL4090937 0.89 CYP3A4 (0.67) TSHRUSP2KMT2AMEN1LMNA
SCHEMBL4090305 0.89 HTT (0.66) ACP1TSHRUSP2KMT2AMEN1
SCHEMBL1084210 0.85 ACP1 (0.81) ACP1HIF1ATSHRUSP2KMT2A
SCHEMBL1084295 0.84 ACP1 (0.81) ACP1HIF1ATSHRUSP2KMT2A
SCHEMBL4095774 0.84 GBA1 (0.61) ACP1TSHRUSP2MAPTABCG2
SCHEMBL4089260 0.83 ACP1 (1.00) ACP1HIF1ATSHRUSP2KMT2A
SCHEMBL4755891 0.83 LMNA (0.53) ACP1HIF1ATSHRUSP2KMT2A
SCHEMBL1084186 0.82 ACP1 (0.81) ACP1HIF1ATSHRUSP2KMT2A
SCHEMBL1083880 0.82 ACP1 (0.81) ACP1HIF1ATSHRUSP2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 ACP1 3504/4885HIF1A 1496/4885TSHR 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.